| Name | Title | Contact Details |
|---|
Bioject Medical Technologies Inc. is a leader in the development of needle-free injection therapies with over 25 years of experience improving the administration of liquid medications; pharmaceuticals, vaccines, and biologics. Bioject's technology works by forcing liquid medication at high speed through a tiny orifice held against the skin. This creates an ultra-fine stream of fluid that penetrates the skin, delivering medication in a fraction of a second. Bioject's systems are designed to deliver injected medications comfortably, accurately, and quickly - without the use of a needle. Bioject was founded in 1985 to develop needle-free injection systems to improve the comfort and safety of routine injections. From its early work focused on improving the characteristics of these delivery systems, the Company has created a broad technology platform for delivering a wide range of medications and vaccines to the subcutaneous, intramuscular and intradermal depths. Bioject has developed a portfolio of injection systems based on its core technology, the foundation for which is more than 80 issued and pending patents and an extensive body of technical know-how. These include durable devices designed for heavy use in a professional healthcare environment, and small, lightweight injectors designed for home use. With partners, Bioject is also developing inexpensive, pre-filled, disposable injection systems. Further validating its technology, Bioject and its partners have the largest volume of published studies using needle-free injection technology systems. Bioject's strategy is to form strategic partnerships with pharmaceutical, biotechnology, and animal health companies. The result is mutually beneficial agreements with these partners to develop customized injection systems to enhance the delivery of their injected medication or vaccine. Bioject has alliances with leading pharmaceutical, biotechnology, and animal health companies. Bioject's products are also used in public health, Physicians offices, and in cutting edge biomedical research at leading institutions around the globe.
eSight empowers the low vision community and advocates to #SeeNewPossibilities for people with macular degeneration, diabetic retinopathy, and 50+ other conditions that cause vision loss. Founded by electrical engineer, Conrad Lewis, who wanted to help his two legally blind sisters see, eSight has since grown to become the leading sight enhancement platform led by an executive team with the vision to do more. After seven years of research and development, the first eSight Eyewear prototype was released in 2013. Since then, the vision-enhancing electronic technology has changed the lives of thousands of people living with visual impairments and legal blindness by allowing them to retain their independence and achieve greater visual acuity at home, school, work, and play. Soon after the release of eSight 3, Time Magazine named eSight in its list of “The 25 Best Inventions in 2017” and Buzzfeed featured the device on its roster of “6 Inventions Changing British People`s Lives In 2017”. Following eSight 3, the team continued to develop its technology and, in 2020, launched its latest model — eSight 4. It was thoughtfully crafted to be wireless and hands-free allowing users to retain their mobility as well as be lightweight and streamlined for all-day comfort. The eSight 4 was later recognized as the “Best Wearable/Healthcare Hardware/Software of 2021” by the Tech Ascension Awards, which honors companies that possess the most innovative technology in their respective industry.
TDK is a Mount Prospect, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Juzo is a Cuyahoga Falls, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
John R. Dwyer, Jr., JD, serves as the Chief Financial Officer and General Counsel of Telcare, Inc. Mr. Dwyer served as Principal of CodeRyte, Inc. He served as an Executive Vice President of Doctors Health, Inc. and also served as its Chief Financial Officer for 2 years. He served as a Principal of Graham, Hamilton & Dwyer, Inc. (“GHD“). He served as Chief Executive Officer of e-MEDx. He served as Chief Operating Officer of Active Health Management. He served as Chief Executive Officer of Vetcentric, a specialty on-line pharmacy. Mr. Dwyer served at Diametrics, Inc., where he served as President of California-based high technology Company. Mr. Dwyer began his professional career as an Attorney with Arent, Fox, Kintner, Plotkin & Kahn, the fifth largest law firm in Washington, D.C., where he focused on transactions in the health care and telecommunications industries. He serves as the Chairman of Redbricks.com, LLC. He serves on the Boards of a number of private and not-for-profit organizations including Earth Conservation Corp. He serves as a Director of the Trust for America's Health. He serves on the Executive Council of Leaders Engaged against Alzheimer's Disease (LEAD). He serves as a Director of USAgainstAlzheimer's. He served as the Chairman of Telcare, Inc. and serves as its Director. He served as a Director of CodeRyte, Inc. Mr. Dwyer served as a Member of the Obama Administration's HHS transition team and has played an active role in the HHS, FDA, and Commerce transition and staffing plans of the Administration. He co-founded the first political action committee focused on a particular disease, the Alzheimer's Action PAC. Mr. Dwyer is a frequent Speaker on financing and regulatory issues of critical importance to emerging health technology companies. He has spoken on health information issues, business risks associated with the FDA approval process, and patent insurance at a variety of forums including the BIO/CEO and AdvaMed annual conferences. Mr. Dwyer is a graduate of Marquette University and the Cornell University Law School.